Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

NCT01110733

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • DCH Cancer Treatment Center Tuscaloosa, Alabama, United States
  • Arizona Cancer Center Tucson, Arizona, United States
  • Genesis Cancer Center Hot Springs, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 68 locations
View Trial Details
Completed

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

NCT01059630

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Southern Cancer Center, PC Mobile, Alabama, United States
  • Dr. Donald W. Hill, MD, FACP Casa Grande, Arizona, United States
  • Highlands Oncology Group Rogers, Arkansas, United States
  • Kaiser Permanente - Bellflower Bellflower, California, United States
View all 121 locations
View Trial Details
Completed

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

NCT00343564

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin's Disease, +9 more
Locations
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Cornell University Medical Center New York, United States
  • Memorial Sloan-Kettering Caner Center New York, United States
  • Herbert Irving Comprehensive Cancer Center New York, United States
View Trial Details
Completed

Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma

NCT02340936

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • ICO- Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain
  • ICO- Hospital Duran i Reynals L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital del Mar Barcelona, Spain
  • Hospital Clinic i Provincial de Barcelona Barcelona, Spain
View Trial Details
Completed

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

NCT01685892

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +14 more
Locations
  • UCSD Moores Cancer Center La Jolla, California, United States
  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center Denver, Colorado, United States
  • Weill Cornell Medical College-New York Presbyterian Hospital New York, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Completed

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

NCT01118234

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Landesklinikum Krems, Hämato-onkologisches Service Krems, Lower Austria, Austria
  • A.ö. Bezirkskrankenhaus Hall in Tirol, Innere Medizin / Hämato - Onkologie Hall in Tirol, Tyrol, Austria
  • Universitätsklinik Innsbruck, Innere MEdizin IV / Hämato-Onkologie Innsbruck, Tyrol, Austria
  • A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie Kufstein, Tyrol, Austria
View all 22 locations
View Trial Details
Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
Locations
  • University of California at Los Angeles Los Angeles, California, United States
  • Stanford University School of Medicine Stanford, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • University of Chicago Hospital Chicago, Illinois, United States
View all 15 locations
View Trial Details
Completed

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

NCT01839097

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Yale University New Haven, Connecticut, United States
  • Northeast Georgia Cancer Care, LLC Athens, Georgia, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details

Related conditions